Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | LTA4H | P09960 | 8/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928196 | 0.89 | MC4R (0.50) | KDM4EHRH3LTA4HMC4R | |
| SCHEMBL23928167 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1LMNAHRH3LTA4H | |
| SCHEMBL23291284 | 0.86 | KDM4E (0.45) | KDM4EALDH1A1LMNAHRH3LTA4H | |
| SCHEMBL23928153 | 0.85 | LTA4H (0.64) | KDM4EHRH3LTA4HEPHX2HTT | |
| SCHEMBL23928172 | 0.84 | LTA4H (0.63) | KDM4EALDH1A1HRH3LTA4HEPHX2 | |
| SCHEMBL23928236 | 0.84 | LTA4H (0.63) | KDM4EALDH1A1HRH3LTA4HEPHX2 | |
| SCHEMBL23928208 | 0.81 | HRH3 (0.56) | KDM4EALDH1A1LMNAHRH3LTA4H | |
| SCHEMBL23291315 | 0.81 | HRH3 (0.56) | KDM4EALDH1A1LMNAHRH3LTA4H | |
| SCHEMBL23291212 | 0.79 | HRH3 (0.66) | KDM4EALDH1A1HRH3LTA4H | |
| SCHEMBL23928135 | 0.78 | HRH3 (0.68) | KDM4EALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | KDM4E 3952/4885ALDH1A1 571/4885LMNA 3595/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | KDM4E 3952/4885ALDH1A1 571/4885LMNA 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.